One Month Daily Wear Clinical Evaluation of New Prototype Contact Lenses in Habitual and Neophyte Contact Lens Wearers
18 juni 2018 bijgewerkt door: Johnson & Johnson Vision Care, Inc.
One Month Daily Wear Clinical Evaluation of Three Prototype Soft Contact Lenses in a Population of Habitual and Neophyte Contact Lens Wearers
There will be four study lenses tested; one marketed lens, and three prototype study lenses.
Subjects will be randomized to one of the four study lenses which will be worn in a daily wear modality, with a two week replacement.
Studie Overzicht
Toestand
Voltooid
Conditie
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Werkelijk)
80
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studie Locaties
-
-
Tamil Nadu
-
Chennai, Tamil Nadu, Indië, 600 006
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
18 jaar tot 39 jaar (Volwassen)
Accepteert gezonde vrijwilligers
Ja
Geslachten die in aanmerking komen voor studie
Allemaal
Beschrijving
Inclusion Criteria:
- The subject must be between 18 and 39 years of age.
- The subject must be able to read and understand English.
- The subject read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form.
- The subject must not have been a participant in a contact lens or contact lens solution study/investigation in the previous seven days.
- The subject must be willing to wearthe study lenses for at least 6 hours per day, 7 days per week (e.g. does not regularly swim).
- The subject must appear able and willing and able to the adhere to the instructions set forth in this clinical protocol.
- The subject's subjective refraction must result in a vertex corrected spherical contact lens prescription in the range of -1.00D to -4.00D in each eye.
- The subject's refractive astigamatism must be less than or equal to -1.00D in both eyes.
- The subjet must have best corrected visual acuity of 20/30 (6/9 or +0.20 logMAR) or better in each eye.
- The subject must require a visual correction in both eyes (no monofit or monovision allowed).
The subject must have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having:
- No amblyopia
- No evidence of lid abnormality or infection (including blepharitis/meibomitis)
- No conjunctival abnormality or infection.
- No clinically significant slit lamp findings (i.e. stromal edema, vascularization, corneal scaring, infiltrates or abnormal opacities).
- No other active ocular diseases.
Exclusion Criteria:
- Any ocular or systemic allergies or diseases that may interfere with contact lens wear.
- Any systemic diseases, autoimmune disease, or use of medication, which may interfere with contact lens wear.
- Clinically significant (Grade 3 or 4) corneal edeam, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear.
- Any ocular infection.
- Any corneal distortion resulting from previous hard or rigid permeable contact lens wear.
- Pregnancy or lactation (subjects who become pregnant during the study will be discontinued).
- No extended wear in the last 3 months.
- Diabetes.
- Infectious diseases (e.g. hepatitis, tuberculosis) or immunosuppressive disease (e.g. HIV).
- Has had refractive surgery.
- Employee of VRF with direct involvement in the study or a family member of the clinic.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Actieve vergelijker: etafilcon A
Marketed control soft contact lens
|
worn in a daily wear modality; lenses will be replaced after 2 weeks
|
|
Experimenteel: Prototype E1
Investigational soft contact lens
|
worn in a daily wear modality; lenses will be replaced after 2 weeks
Andere namen:
|
|
Experimenteel: Prototype E2
Investigational soft contact lens
|
worn in a daily wear modality; lenses will be replaced after 2 weeks
Andere namen:
|
|
Experimenteel: Prototype E3
Investigational soft contact lens
|
worn in a daily wear modality; lenses will be replaced after 2 weeks
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Corneal Staining (Area)
Tijdsspanne: Baseline and 4-Week Follow-up
|
Corneal Staining Area was collected at baseline and 4- week evaluations in both eyes using a slit lamp and was graded with a 11-point scale (i.e.
Grade 0= 0% of region covered, Grade 1 =10% of region covered, Grade 2 = 20% of region covered, Grade 3 = 30% of region covered, Grade 4= 40% of region covered, Grade 5 = 50% of region covered, Grade 6 = 60% of region covered,Grade 7 = 70% of region covered, Grade 8 = 80% of region covered, Grade 9 = 90% of region covered and Grade 10 = 100% of region covered).
Central, interior, nasal, temporal and superior locations were evaluated.
The average grade for each lens and time point was reported.
|
Baseline and 4-Week Follow-up
|
|
Corneal Staining (Depth)
Tijdsspanne: Baseline and 4-Week Follow-up
|
Corneal Staining Depth was collected at baseline and 4- week evaluations in both eyes using a slit lamp and was graded with a 4-point scale (i.e.
Grade 0= None, Grade 1 =Superficial epithelial, Grade 2 = Full epithelial, Grade 3 =stromal glow).
Central, interior, nasal, temporal and superior locations were evaluated.
The average grade for each lens and time point was reported.
|
Baseline and 4-Week Follow-up
|
|
Corneal Staining (Type)
Tijdsspanne: Baseline and 4-Week Follow-up
|
Corneal Staining was collected at baseline and 4- week evaluations in both eyes using a slit lamp and was graded with a 5-point scale (i.e.
Grade 0= None, Grade 1 =Micropunctate, Grade 2 = Macropunctate, Grade 3 = Coalesced Macropunctate and Grade 4 = Patch (greater or equal to 1mm).
Central, interior, nasal, temporal and superior locations were evaluated.
The average grade for each lens and time point was reported.
|
Baseline and 4-Week Follow-up
|
|
Limbal Conjunctival Redness
Tijdsspanne: Baseline and 2-Week Follow-up
|
Limbal Conjunctival Redness was assessed for each subject and eye at baseline and 2-week follow-up evaluations.
Limbal Redness was assessed in 4 regions Inferior, Nasal, Temporal and Superior and Graded using an Efron Grading scale for limbal redness in 0.5 unit increments (Grade 0:None, Grade 1:Trace, Grade 2: Mild, Grade 3: Moderate and Grade 4: Severe).
The average Grade across all four regions can range from 0 to 16 where lower values indicate better performance.
The average Grade for each individual region can range from 0 to 4. The average grade across all regions was reported for each lens and time point.
|
Baseline and 2-Week Follow-up
|
|
Bulbar Conjunctival Redness
Tijdsspanne: Baseline and 2-Week Follow-up
|
Bulbar Conjunctival Redness was assessed for each subject and eye at baseline and 2-week follow-up evaluations.
Bulbar Redness was assessed in 4 regions Inferior, Nasal, Temporal and Superior and Graded using an Efron Grading scale for bulbar redness in 0.5 unit increments (Grade 0:None, Grade 1:Trace, Grade 2: Mild, Grade 3: Moderate and Grade 4: Severe).
The average Grade across all four regions can range from 0 to 16 where lower values indicate better performance.
The average Grade for each individual region can range from 0 to 4. The average grade across all regions was reported for each lens and time point.
|
Baseline and 2-Week Follow-up
|
|
Visual Acuity (LogMAR)
Tijdsspanne: 4-Week Follow-up
|
Visual Acuity (LogMAR) was assessed bionocularly at the 4-week follow-up evaluations.
The average visual acuity (LogMAR) for each lens was reported.
|
4-Week Follow-up
|
|
Lens Fitting Characteristics
Tijdsspanne: Post Lens Fitting and 4-Week Follow-up
|
Lens fit was assessed for each subject eye at post lens fitting and 4- week follow-up evaluations.
Lens fit is a binary response as acceptable or unacceptable lens fit.
The percentage of eyes with acceptable lens fit was reported.
|
Post Lens Fitting and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Burning/Stinging)
Tijdsspanne: Baseline and 4-Week Follow-up
|
The Ocular symptom Burning/Stinging was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Corneal Edema
Tijdsspanne: Baseline and 4-Week Follow-up
|
Corneal Edema was assessed using a bio-microscope at baseline and 4- week evaluations in both eyes and was graded with a 5-point scale (Grade 0= None, Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe).
The Percentage of eyes with Grade 3 or higher was reported.
|
Baseline and 4-Week Follow-up
|
|
Conjunctival Injection
Tijdsspanne: Baseline and 4-Week Follow-up
|
Conjunctival Injection was assessed using a bio-microscope at baseline and 4- week evaluations in both eyes and was graded with a 5-point scale (Grade 0= None, Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe).
The Percentage of eyes with Grade 3 or higher was reported.
|
Baseline and 4-Week Follow-up
|
|
Corneal Neovascularization
Tijdsspanne: Baseline and 4-Week Follow-up
|
Corneal Neovascularization was assessed using a bio-microscope at baseline and 4- week evaluations in both eyes and was graded with a 5-point scale (Grade 0= None, Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe).
The Percentage of eyes with Grade 3 or higher was reported.
|
Baseline and 4-Week Follow-up
|
|
Corneal Staining
Tijdsspanne: Baseline and 4-Week Follow-up
|
Corneal Staining was assessed using a bio-microscope at baseline and 4- week evaluations in both eyes and was graded with a 5-point scale (Grade 0= None, Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe).
The Percentage of eyes with Grade 3 or higher was reported.
|
Baseline and 4-Week Follow-up
|
|
Tarsal Abnormalities
Tijdsspanne: 1-, 2- and 4-Week Follow-up
|
Tarsal abnormalities were assessed using a biomicroscope at baseline, post lens fitting, 1-, 2- and 4- week evaluations in both eyes and was graded with a 5-point scale (Grade 0, 1, 2, 3 and 4) with grade 0 represents the absence of abnormalities and 1 to 4 representing successively worse abnormalities (i.e.
Grade 0= None, Grade 1 = trace, Grade 2 = Mild, Grade 3 = moderate and Grade 4 = severe).
The percentage of eyes with Grade 3 or higher was reported.
|
1-, 2- and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Cloudy/Blurry/Hazy)
Tijdsspanne: Baseline and 4-Week Follow-up
|
The Ocular symptom Cloudy/Blurry/Hazy was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Dryness)
Tijdsspanne: Baseline and 4-Week Follow-up
|
The Ocular symptom Dryness was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Grittiness/Foreign Body Sensation)
Tijdsspanne: Baseline and 4-Week Follow-up
|
The Ocular symptom Grittiness/Foreign Body Sensation was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Irritation/Discomfort)
Tijdsspanne: Baseline and 4-Week Follow-up
|
The Ocular symptom Irritation/Discomfort was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Itchiness/Scratchiness)
Tijdsspanne: Baseline and 4-Week Follow-up
|
The Ocular symptom Itchiness/Scratchiness was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Lens Awareness)
Tijdsspanne: Baseline and 4-Week Follow-up
|
The Ocular symptom Lens awareness was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Redness)
Tijdsspanne: Baseline and 4-Week Follow-up
|
The Ocular symptom Redness wasassessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
|
Percentage of Reported Ocular Symptoms (Variable Vision)
Tijdsspanne: Baseline and 4-Week Follow-up
|
The Ocular symptom Variable Vision was assessed by an individual item on a questionnaire and are subject reported, using the response scale of (N/A or Not recorded, Mild and rarely interferes with wear, Moderate and/or occasionally interferes with wear and Severe and/or frequently interferes with wear.
The percentage of Moderate or severe symptoms were reported for the initial visit as well as the 1 month follow-up.
|
Baseline and 4-Week Follow-up
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Werkelijk)
6 februari 2014
Primaire voltooiing (Werkelijk)
25 juni 2014
Studie voltooiing (Werkelijk)
25 juni 2014
Studieregistratiedata
Eerst ingediend
5 maart 2014
Eerst ingediend dat voldeed aan de QC-criteria
6 maart 2014
Eerst geplaatst (Schatting)
7 maart 2014
Updates van studierecords
Laatste update geplaatst (Werkelijk)
19 juni 2018
Laatste update ingediend die voldeed aan QC-criteria
18 juni 2018
Laatst geverifieerd
1 juli 2017
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- CR-5146
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Ja
product vervaardigd in en geëxporteerd uit de V.S.
Ja
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .